Parnax Lab Limited engages in the manufacture and export of pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; cosmetic products; herbal products; and nutraceutical products. It also provides Oral Formulations, such as cough expectorants, antacids, antihistamines, multi-vitamins, enzyme preparations, pediatric formulations, formulations for geriatrics, highly viscous products, and suspensions. In addition, the company provides drug identification and development services; in- and out-licensing services; and contract research and manufacturing services The company was formerly known as Krishna-Deep Trade & Investments Limited and changed its name to Parnax Lab Limited in April 2012. The company was incorporated in 1982 and is headquartered in Mumbai, India.
| Current Price | ₹121.75 |
|---|---|
| Market Cap | ₹140 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 11.9 |
| Return on Equity | 13.22% |
| 52-Week Range | ₹96.25 – ₹182.00 |
| Beta (1Y) | 0.33 |
Parnax Lab Ltd. is trading at ₹121.75, with a market capitalisation of ₹140 Cr.
Parnax Lab Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Parnax Lab Ltd. has a P/E of 11.9 and a return on equity of 13.22%.